Limits...
Glucose-lowering effect of DLBS3233 is mediated through phosphorylation of tyrosine and upregulation of PPARγ and GLUT4 expression.

Tandrasasmita OM, Wulan DD, Nailufar F, Sinambela J, Tjandrawinata RR - Int J Gen Med (2011)

Bottom Line: DLBS3233 was also found to enhance the expression of genes associated with increased insulin signaling and sensitivity, such as peroxisome proliferator-activated receptor gamma, phosphatidylinositol-3 kinase, Akt, and glucose transporter 4.In addition, glucose transporter 4 protein levels were seen to increase as a result of DLBS3233 administration.DLBS3233, as a combination of herbal extracts, holds promise in the treatment of type 2 diabetes, and possibly also in prevention of the disease.

View Article: PubMed Central - PubMed

Affiliation: Division of Molecular Pharmacology.

ABSTRACT

Background: DLBS3233 is a standardized extract combination containing Lagerstroemia speciosa and Cinnamomum burmannii. The effect of DLBS3233 on glucose uptake, adiponectin secretion, and insulin signaling was examined in this study.

Methods: 3T3 Swiss albino preadipocytes and adipocytes were used to investigate gene expression detected using the reverse transcription polymerase chain reaction method. Immunoblotting assay and in vitro glucose uptake assay were also carried out in the experiment.

Results: DLBS3233 was seen to increase phosphorylation at the tyrosine residue of the insulin receptor substrate. DLBS3233 was also found to enhance the expression of genes associated with increased insulin signaling and sensitivity, such as peroxisome proliferator-activated receptor gamma, phosphatidylinositol-3 kinase, Akt, and glucose transporter 4. In addition, glucose transporter 4 protein levels were seen to increase as a result of DLBS3233 administration. The combination of extracts also increased glucose uptake and adiponectin secretion, and decreased resistin secretion significantly relative to control cells. Moreover, DLBS3233 administered to insulin-resistant Wistar rats showed an ability to control blood sugar, insulin levels, and other lipoproteins, including high-density lipoprotein, low-density lipoprotein, triglycerides, and total cholesterol.

Conclusion: DLBS3233, as a combination of herbal extracts, holds promise in the treatment of type 2 diabetes, and possibly also in prevention of the disease.

No MeSH data available.


Related in: MedlinePlus

DLBS3233 increases glucose uptake in 3T3 Swiss albino cells compared with untreated cells. A) Glucose uptake level of 3T3 Swiss albino preadipocytes and adipocytes in normal and insulin-resistant condition. B) Effect of DLBS3233 5 μg/mL and pioglitazone 0.02 μM on glucose uptake in normal and insulin-resistant 3T3 Swiss albino adipocytes. C) DLBS3233 5 μg/mL enhances glucose uptake activity of 3T3 Swiss albino insulin-resistant adipocytes as potently as pioglitazone in time-dependent manner. Results are mean value ± standard deviation of two independent experiments.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3108202&req=5

f1-ijgm-4-345: DLBS3233 increases glucose uptake in 3T3 Swiss albino cells compared with untreated cells. A) Glucose uptake level of 3T3 Swiss albino preadipocytes and adipocytes in normal and insulin-resistant condition. B) Effect of DLBS3233 5 μg/mL and pioglitazone 0.02 μM on glucose uptake in normal and insulin-resistant 3T3 Swiss albino adipocytes. C) DLBS3233 5 μg/mL enhances glucose uptake activity of 3T3 Swiss albino insulin-resistant adipocytes as potently as pioglitazone in time-dependent manner. Results are mean value ± standard deviation of two independent experiments.

Mentions: In order to study glucose uptake in different adipocyte conditions, the 3T3 fibroblast Swiss albino cells were allowed to differentiate into mature adipocytes so that they could be used as a cellular model of insulin resistance in diabetes. In the insulin-resistant condition, their glucose uptake capacity was used to simulate the actual phenomenon in the clinical setting. It was found that the insulin-resistant preadipocytes and mature adipocytes took up glucose at a much lower rate than their normal counterparts (Figure 1A). In addition, the onset of glucose uptake was found to be earlier in normal preadipocytes and adipocytes when compared with those that were insulin-resistant. This suggests that glucose transport impairment had occurred in the insulin-resistant preadipocytes and adipocytes, a clinically important phenomenon in predicting the onset of type 2 diabetes even in seemingly normal individuals.


Glucose-lowering effect of DLBS3233 is mediated through phosphorylation of tyrosine and upregulation of PPARγ and GLUT4 expression.

Tandrasasmita OM, Wulan DD, Nailufar F, Sinambela J, Tjandrawinata RR - Int J Gen Med (2011)

DLBS3233 increases glucose uptake in 3T3 Swiss albino cells compared with untreated cells. A) Glucose uptake level of 3T3 Swiss albino preadipocytes and adipocytes in normal and insulin-resistant condition. B) Effect of DLBS3233 5 μg/mL and pioglitazone 0.02 μM on glucose uptake in normal and insulin-resistant 3T3 Swiss albino adipocytes. C) DLBS3233 5 μg/mL enhances glucose uptake activity of 3T3 Swiss albino insulin-resistant adipocytes as potently as pioglitazone in time-dependent manner. Results are mean value ± standard deviation of two independent experiments.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3108202&req=5

f1-ijgm-4-345: DLBS3233 increases glucose uptake in 3T3 Swiss albino cells compared with untreated cells. A) Glucose uptake level of 3T3 Swiss albino preadipocytes and adipocytes in normal and insulin-resistant condition. B) Effect of DLBS3233 5 μg/mL and pioglitazone 0.02 μM on glucose uptake in normal and insulin-resistant 3T3 Swiss albino adipocytes. C) DLBS3233 5 μg/mL enhances glucose uptake activity of 3T3 Swiss albino insulin-resistant adipocytes as potently as pioglitazone in time-dependent manner. Results are mean value ± standard deviation of two independent experiments.
Mentions: In order to study glucose uptake in different adipocyte conditions, the 3T3 fibroblast Swiss albino cells were allowed to differentiate into mature adipocytes so that they could be used as a cellular model of insulin resistance in diabetes. In the insulin-resistant condition, their glucose uptake capacity was used to simulate the actual phenomenon in the clinical setting. It was found that the insulin-resistant preadipocytes and mature adipocytes took up glucose at a much lower rate than their normal counterparts (Figure 1A). In addition, the onset of glucose uptake was found to be earlier in normal preadipocytes and adipocytes when compared with those that were insulin-resistant. This suggests that glucose transport impairment had occurred in the insulin-resistant preadipocytes and adipocytes, a clinically important phenomenon in predicting the onset of type 2 diabetes even in seemingly normal individuals.

Bottom Line: DLBS3233 was also found to enhance the expression of genes associated with increased insulin signaling and sensitivity, such as peroxisome proliferator-activated receptor gamma, phosphatidylinositol-3 kinase, Akt, and glucose transporter 4.In addition, glucose transporter 4 protein levels were seen to increase as a result of DLBS3233 administration.DLBS3233, as a combination of herbal extracts, holds promise in the treatment of type 2 diabetes, and possibly also in prevention of the disease.

View Article: PubMed Central - PubMed

Affiliation: Division of Molecular Pharmacology.

ABSTRACT

Background: DLBS3233 is a standardized extract combination containing Lagerstroemia speciosa and Cinnamomum burmannii. The effect of DLBS3233 on glucose uptake, adiponectin secretion, and insulin signaling was examined in this study.

Methods: 3T3 Swiss albino preadipocytes and adipocytes were used to investigate gene expression detected using the reverse transcription polymerase chain reaction method. Immunoblotting assay and in vitro glucose uptake assay were also carried out in the experiment.

Results: DLBS3233 was seen to increase phosphorylation at the tyrosine residue of the insulin receptor substrate. DLBS3233 was also found to enhance the expression of genes associated with increased insulin signaling and sensitivity, such as peroxisome proliferator-activated receptor gamma, phosphatidylinositol-3 kinase, Akt, and glucose transporter 4. In addition, glucose transporter 4 protein levels were seen to increase as a result of DLBS3233 administration. The combination of extracts also increased glucose uptake and adiponectin secretion, and decreased resistin secretion significantly relative to control cells. Moreover, DLBS3233 administered to insulin-resistant Wistar rats showed an ability to control blood sugar, insulin levels, and other lipoproteins, including high-density lipoprotein, low-density lipoprotein, triglycerides, and total cholesterol.

Conclusion: DLBS3233, as a combination of herbal extracts, holds promise in the treatment of type 2 diabetes, and possibly also in prevention of the disease.

No MeSH data available.


Related in: MedlinePlus